Corvus Pharmaceuticals (CRVS) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$2.9 million.
- Corvus Pharmaceuticals' Enterprise Value rose 3873.93% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year increase of 3873.93%. This contributed to the annual value of -$8.7 million for FY2024, which is 3074.48% up from last year.
- Latest data reveals that Corvus Pharmaceuticals reported Enterprise Value of -$2.9 million as of Q3 2025, which was up 3873.93% from -$14.7 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Enterprise Value registered a high of -$2.9 million during Q3 2025, and its lowest value of -$31.5 million during Q1 2022.
- Over the past 4 years, Corvus Pharmaceuticals' median Enterprise Value value was -$12.6 million (recorded in 2023), while the average stood at -$13.7 million.
- Over the last 5 years, Corvus Pharmaceuticals' Enterprise Value had its largest YoY gain of 7672.22% in 2024, and its largest YoY loss of 9379.73% in 2024.
- Corvus Pharmaceuticals' Enterprise Value (Quarter) stood at -$13.2 million in 2022, then rose by 4.1% to -$12.6 million in 2023, then skyrocketed by 30.74% to -$8.7 million in 2024, then soared by 67.2% to -$2.9 million in 2025.
- Its Enterprise Value stands at -$2.9 million for Q3 2025, versus -$14.7 million for Q2 2025 and -$5.0 million for Q1 2025.